Cynosure's PicoSure Picosecond Laser Workstation receives FDA clearance for treatment of wrinkles

Cynosure, Inc. (NASDAQ: CYNO), a leader in laser- and light-based aesthetic treatments for non-invasive and minimally invasive applications, today announced that it has received FDA 510(k) clearance to market its flagship PicoSure Picosecond Laser Workstation for the treatment of wrinkles with the Company's new disposable energy delivery system, the FOCUS lens array. In the fourth quarter of 2012, PicoSure became the world's first picosecond device to receive FDA clearance for the removal of tattoos and benign pigmented lesions.

"This clearance complements our recently received approval to market PicoSure for the treatment of acne scars, and demonstrates the breadth of our FOCUS lens array technology to address additional high-volume indications," said Cynosure Chairman and Chief Executive Officer Michael Davin. "According to the independent industry research and analysis firm Medical Insight, worldwide sales for skin rejuvenation platforms are projected to grow at a compound annual growth rate of 8.2 percent through 2018 to $512.6 million. We believe this large addressable market represents a significant growth opportunity for Cynosure and provides another avenue to drive our disposables revenue."

SOURCE Cynosure, Inc.